Dosage and formulation have been investigated and show differences; injectable GLP-1 agonists (e.g., semaglutide) typically yield superior weight loss efficacy compared to oral forms in obesity studies, attributed to better bioavailability and adherence, though OSA-specific comparisons are scarce (114, 115). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.